Cargando…
Treat-to-target in PsA: methods and necessity
With increasing recognition of the high burden and impact of psoriatic arthritis (PsA) and the growing number of therapeutic options, there has been an intensifying focus on treatment strategy in recent years. In 2015, the Tight Control of Psoriatic Arthritis study confirmed the clinical benefit of...
Autores principales: | Dures, Emma, Shepperd, Sasha, Mukherjee, Sandeep, Robson, Jo, Vlaev, Ivo, Walsh, Nicola, Coates, Laura C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046962/ https://www.ncbi.nlm.nih.gov/pubmed/32071281 http://dx.doi.org/10.1136/rmdopen-2019-001083 |
Ejemplares similares
-
Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)
por: Mease, Philip J, et al.
Publicado: (2018) -
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
por: Mease, Philip J, et al.
Publicado: (2021) -
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
por: Richette, Pascal, et al.
Publicado: (2023) -
Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial
por: Helliwell, Philip S, et al.
Publicado: (2022) -
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
por: Coates, Laura C, et al.
Publicado: (2023)